Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
Subscribe To Our Newsletter & Stay Updated